Key clinical point: The PCSK9 inhibitor alirocumab significantly reduced peripheral artery disease (PAD) and venous thromboembolism (VTE) events and ischemic strokes in patients with recent acute coronary syndrome event.
Major finding: The incidence of PAD and VTE events fell by 31% on alirocumab treatment, compared with placebo.
Study details: Prespecified, ancillary analyses from ODYSSEY Outcomes, a multicenter, randomized trial with 18,924 patients.
Disclosures: ODYSSEY Outcomes was sponsored by Sanofi and Regeneron, the companies that market alirocumab (Praluent). Dr. Schwartz has received research support from Sanofi and from Resverlogix, Roche, and The Medicines Company. Dr. Jukema has been a speaker for and received research support from Sanofi Regeneron, and has also been a speaker for Amgen, MSD, and Roche, and has also received research support from Biotronik.
Schwartz GG et al. AHA 2019, Abstract 309; Jukema JW et al. American Heart Association, Abstract 334.